about
An Omics Perspective on Candida Infections: Toward Next-Generation Diagnosis and TherapyPruritus in female patientsTargeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseasesBlack yeasts and their filamentous relatives: principles of pathogenesis and host defenseDissecting Candida albicans Infection from the Perspective of C. albicans Virulence and Omics Approaches on Host-Pathogen Interaction: A ReviewExperimental Models of Vaginal Candidiasis and Their Relevance to Human CandidiasisPrimary immunodeficiencies underlying fungal infectionsDifferent Brain Regions are Infected with Fungi in Alzheimer's Disease.The mycobiota: interactions between commensal fungi and the host immune system.CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans.A systematic evaluation of high-dimensional, ensemble-based regression for exploring large model spaces in microbiome analyses.Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis.Immune Interactions with Pathogenic and Commensal Fungi: A Two-Way StreetNociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous ImmunityGenetic Susceptibility to Fungal Infections: What is in the Genes?The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infectionsImmunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.Mannose-binding lectin codon 54 gene polymorphism and vulvovaginal candidiasis: a systematic review and meta-analysis.Progresses in vaginal microflora physiology and implications for bacterial vaginosis and candidiasis.New fungal diagnostics.Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects.Protective immune responses to fungal infections.Immune responses to airborne fungi and non-invasive airway diseases.Immune defence against Candida fungal infections.Alarmin(g) the innate immune system to invasive fungal infectionsPharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Central Role for Dermal Fibroblasts in Skin Model Protection against Candida albicans.Inhibition of CBLB protects from lethal Candida albicans sepsis.Endogenous Candida endophthalmitis and osteomyelitis associated with CARD9 deficiency.Editorial: An Omics Perspective on Fungal Infection: Toward Next-Generation Diagnosis and Therapy.TLR2 polymorphism and susceptibility to vulvovaginal colonisation by Candida species.Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1.Modulating Host Signaling Pathways to Promote Resistance to Infection by Candida albicans.The interaction effect of rs4077515 and rs17019602 increases the susceptibility to IgA nephropathy.Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Innate Immunity to Mucosal Candida Infections.Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy.Recognition of Candida albicans by gingival fibroblasts: The role of TLR2, TLR4/CD14, and MyD88.Modulation of Cyp450, ALS1 and COX-2 signaling pathways induced by Candida albicans infection via novel antifungal agents.Mannose-Binding Lectin: A Potential Therapeutic Candidate against Candida Infection.
P2860
Q26766720-0728E208-90AB-4488-AA7D-A468094F1A68Q26828038-6FED522B-23D4-4D92-979A-2713C9330A14Q27010345-71FBE14D-4B8A-4C2B-8311-6F1301FB40B1Q27028032-3FA3E599-0505-417D-8263-DEA506BA4BB3Q28067088-12BFE2F9-B273-481C-8D49-F5312E399DB8Q28077299-DEDFE765-4B70-4278-BDB1-122567D4A3BEQ33902831-55AF09BB-4CF2-4863-A1A1-C759FD9483CBQ34045152-863283AD-5956-4067-86C3-CE02F1F03C16Q35096262-97640A39-87E5-462D-B101-D3269A87E8AEQ35098244-EDE45FC6-CBCC-4894-BEDA-8A6611E63E51Q35119273-8C382E9A-1F58-4FD0-B0EF-FE4116747539Q35451557-4C7A59E1-765C-4945-816C-C73FE7EF958FQ35847333-0E67CFD5-C133-4BA8-9224-A602750CB67AQ36165375-9570CAF7-57A7-41AD-BC6B-B64B4132229BQ37183884-0326EA5C-7482-452A-A934-7A682A644902Q37374119-1ADFC0F3-48CF-462F-AB41-1FC741A28E90Q37481373-CAD98070-D412-456F-9B73-7B57B72A1C41Q37544133-F3CCF325-4BB5-408F-8A83-362652CE3F73Q37741788-F1B08CA3-940B-4E62-BBE7-7B1729057392Q38231463-FD45B03A-3667-4D11-A97B-5D0056D8D081Q38232781-E8CD21B3-C8C4-46DF-9976-FEF60E4EB971Q38247209-64BE91FD-8510-4A02-B09F-464D756E0406Q38287190-AA3ECC95-C5AF-4844-952B-408A05B5D08BQ38590007-3CDB8FDA-61C3-40F8-B130-D0C20F1FEBDCQ38879361-01E05739-0B15-4A22-A710-349DF76E3519Q38880522-8886AEE1-4EBA-4AF8-B585-6BD230F25D3CQ40268085-902F20A9-8DDE-497B-9F65-80A2CE758493Q40610011-916FFB04-B273-4AF1-9A36-D38FDA4157FBQ40768110-08A4963A-4E20-4AE2-83E9-0566CDBB3327Q42327974-61AA9E4D-988D-4C4E-B3CC-5EDC4133C40CQ46426758-77366FC0-F2C2-4419-B36C-A63747A63C49Q47129238-2718C69E-CCC9-4F0B-9637-44E11F0225A9Q47334511-C8BC9A44-A901-449D-A975-4608A61F0532Q47662587-BB39448A-E4F2-4823-907F-F88F8AA22BD1Q48159180-CDF8C134-4AC8-4E4E-9ABE-CCD52C6B2A7DQ48163042-F3C8F9AE-45FF-4D0B-9C34-2B3F1775973BQ49679946-1D8B5E40-EDA2-4EEB-8BBD-1A3CC602E56BQ50058357-9C0BEAFE-7EDF-4D71-975A-502C9DA08C5DQ52647827-9BE6CA29-C8DE-456C-87BF-7EDB46798121Q55004750-3E134833-0A40-437C-9A4F-925EBDF76296
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Genetic susceptibility to Candida infections.
@ast
Genetic susceptibility to Candida infections.
@en
Genetic susceptibility to Candida infections.
@nl
type
label
Genetic susceptibility to Candida infections.
@ast
Genetic susceptibility to Candida infections.
@en
Genetic susceptibility to Candida infections.
@nl
prefLabel
Genetic susceptibility to Candida infections.
@ast
Genetic susceptibility to Candida infections.
@en
Genetic susceptibility to Candida infections.
@nl
P2093
P2860
P921
P356
P1476
Genetic susceptibility to Candida infections.
@en
P2093
Bart Jan Kullberg
Frank L van de Veerdonk
Mihai G Netea
Sanne P Smeekens
P2860
P304
P356
10.1002/EMMM.201201678
P5008
P577
2013-04-30T00:00:00Z
2013-06-01T00:00:00Z